Demographic, multi-morbidity and genetic impact on myocardial involvement and its recovery from COVID-19: protocol design of COVID-HEART—a UK, multicentre, observational study

Journal of Cardiovascular Magnetic Resonance

the COVID-HEART investigators¹  Chiara Bucciarelli-Ducci²  Dana Dawson³  Vanessa M. Ferreira⁴  Stefan Neubauer⁴  Christopher A. Miller⁵  Marianna Fontana⁶  Peter W. Macfarlane⁷  James C. Moon⁸  Colin Berry⁹  Miroslawa Gorecka^1,10  John P. Greenwood^1,10  Sanjay Prasad^1,11  Alex McConnachie^1,12  Amedeo Chiribiri^1,13  Marc R. Dweck^1,14  Gerry P. McCann^1,15 

[1] ;Bristol Heart Institute, Bristol NIHR Cardiovascular Research Centre, University of Bristol and University Hospitals Bristol and Weston NHS Trust;Department of Cardiology, Aberdeen Cardiovascular and Diabetes Centre, Aberdeen Royal Infirmary and University of Aberdeen;Division of Cardiovascular Medicine, Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, British Heart Foundation Centre of Research Excellence, Oxford NIHR Biomedical Research Centre, University of Oxford;Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester;Division of Medicine, Royal Free Hospital, University College London;Electrocardiology Core Laboratory, Institute of Health and Wellbeing, University of Glasgow;Institute of Cardiovascular Science, University College London;Institute of Cardiovascular and Medical Sciences and British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow;Institute of Cardiovascular and Metabolic Medicine, University of Leeds;National Heart and Lung Institute, Imperial College;Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow;School of Biomedical Engineering and Imaging Sciences, King’s College London, BHF Centre of Excellence and the NIHR Biomedical Research Centre at Guy’s and St. Thomas’ NHS Foundation Trust, The Rayne Institute, St. Thomas’ Hospital;University of Edinburgh and British Heart Foundation Centre for Cardiovascular Science;University of Leicester and The NIHR Leicester Biomedical Research Centre, Glenfield Hospital;

关键词: COVID-19;    Coronavirus;    Cardiovascular magnetic resonance;    Myocarditis;    Myopericarditis;    Myocardial infarction;   

DOI  :  10.1186/s12968-021-00752-1

来源: DOAJ

【 摘 要 】

Abstract Background Although coronavirus disease 2019 (COVID-19) is primarily a respiratory illness, myocardial injury is increasingly reported and associated with adverse outcomes. However, the pathophysiology, extent of myocardial injury and clinical significance remains unclear. Methods COVID-HEART is a UK, multicentre, prospective, observational, longitudinal cohort study of patients with confirmed COVID-19 and elevated troponin (sex-specific > 99th centile). Baseline assessment will be whilst recovering in-hospital or recently discharged, and include cardiovascular magnetic resonance (CMR) imaging, quality of life (QoL) assessments, electrocardiogram (ECG), serum biomarkers and genetics. Assessment at 6-months includes repeat CMR, QoL assessments and 6-min walk test (6MWT). The CMR protocol includes cine imaging, T1/T2 mapping, aortic distensibility, late gadolinium enhancement (LGE), and adenosine stress myocardial perfusion imaging in selected patients. The main objectives of the study are to: (1) characterise the extent and nature of myocardial involvement in COVID-19 patients with an elevated troponin, (2) assess how cardiac involvement and clinical outcome associate with recognised risk factors for mortality (age, sex, ethnicity and comorbidities) and genetic factors, (3) evaluate if differences in myocardial recovery at 6 months are dependent on demographics, genetics and comorbidities, (4) understand the impact of recovery status at 6 months on patient-reported QoL and functional capacity. Discussion COVID-HEART will provide detailed characterisation of cardiac involvement, and its repair and recovery in relation to comorbidity, genetics, patient-reported QoL measures and functional capacity. Clinical Trial registration: ISRCTN 58667920. Registered 04 August 2020.

【 授权许可】

Unknown